Cancer Advisor

Modern oncology is rapidly evolving from a “one-size-fits-all” model into a far more individualized approach known as precision oncology. At the center of this transformation are: Genomics Nutrigenomics Biomarker testing Tumor sequencing AI-driven molecular analysis Precision nutrition Together, these fields are reshaping how clinicians understand cancer risk, treatment response, metabolism, inflammation, and even dietary interventions. The convergence of cancer genomics and personalized nutrition may become one of the defining themes of next-generation oncology. Genetics vs Genomics: Why the Difference Matters Many people use the terms “genetics” and “genomics” interchangeably, but they are not the same. ( Cancer.org ) Genetics Genetics focuses primarily on individual inherited genes passed down through families. Examples include: BRCA1 and BRCA2 mutations Lynch syndrome Familial adenomatous polyposis (FAP) These inherited mutations are often called germline mutations. They may increa...

Cancer is not just a genetic disease. It is also deeply influenced by metabolism, inflammation, immunity, hormones, blood vessel growth, and the tumor microenvironment. One of the most fascinating concepts in modern oncology is that tumors require a constant supply of nutrients and oxygen in order to grow. Without access to blood vessels and metabolic fuel, many tumors struggle to expand. This idea helped popularize the phrase: “Starving cancer cells.” But what does that actually mean scientifically? The answer lies in understanding: Tumor angiogenesis (blood vessel growth) Cancer metabolism Chronic inflammation Insulin and glucose signaling Immune system regulation Nutrient-sensing pathways Dietary considerations for a cancer patient can be viewed as catering to two mouths: one of the patient, governed by personal choices and the body’s metabolic responses to feeding or fasting; and the other of the tumor, which imposes its own demands.  A 2025 review in Nature  examines diet...

Key message: Lifestyle interventions do not replace immunotherapy — but they can meaningfully influence who responds, how well, and how long responses last by shaping metabolism, inflammation, and immune fitness. Why Lifestyle Matters in the Era of Immunotherapy Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4) have transformed cancer care, yet: Only 20–40% of patients achieve durable responses Many experience immune-related adverse events Metabolic and inflammatory status strongly influence outcomes Lifestyle factors act upstream of the immune system, affecting T-cell energetics, cytokine balance, gut microbiota, and systemic inflammation — all critical to immunotherapy success. Metabolic Health: The Primary Modifier of Immune Response Insulin Resistance and Hyperglycemia Poor glycemic control is associated with: Impaired T-cell activation Increased regulatory T-cell dominance Reduced response rates to checkpoint inhibitors Conversely, improved insulin sensitivity supports: CD8+ T-...

From “Undruggable” to One of the Most Important Targets in Cancer Medicine For decades, KRAS mutations were considered one of the most challenging problems in oncology. The protein was structurally smooth, biologically complex, and notoriously resistant to drug binding. It became known in medical literature as “undruggable.” That narrative changed dramatically in the early 2020s. Today, KRAS is no longer a scientific dead end—it is one of the most actively targeted oncogenic drivers in modern precision medicine. Multiple generations of KRAS inhibitors now exist, and treatment strategies are evolving from single-mutation targeting toward pan-RAS pathway control and combination therapy systems . However, despite major breakthroughs, KRAS-driven cancers remain difficult to cure. The reason is not a lack of drugs—but the adaptability of cancer biology itself. This article provides a complete 2026 update on KRAS inhibitors, including mechanisms, approved therapies, emerging drugs, resistanc...

Key Takeaways Precision nutrition aims to personalize dietary strategies using genetics, metabolism, biomarkers, and microbiome data. Metabolic dysfunction is increasingly linked to cancer biology and treatment response. The gut microbiome may influence immunity and immunotherapy outcomes. Different cancer patients may require very different nutritional approaches. Precision nutrition may eventually become part of systems oncology and personalized medicine. Much of the science remains early-stage and evolving. Cancer treatment is rapidly evolving beyond the traditional “one-size-fits-all” approach. Precision oncology already uses: genomic testing, biomarkers, immunotherapy, and molecular profiling to tailor treatment to individual patients. Now, researchers are beginning to ask a new question: Could nutrition also become personalized based on a patient’s genes, metabolism, microbiome, and tumor biology? This emerging field is known as precision nutrition . Precision nutrition aims to u...

Cancer research is entering a new era where nutrition is no longer viewed simply as “fuel” or calorie intake. Scientists are increasingly studying how nutrients interact with: genes, metabolism, inflammation, immunity, and the tumor microenvironment. This emerging field is called nutrigenomics . Nutrigenomics explores how: food and nutrients may influence gene expression, cellular signaling, and biological pathways involved in health and disease. In oncology, researchers are now investigating whether nutrition could potentially affect: cancer risk, tumor progression, treatment tolerance, immune function, and even responses to therapy. What Is Nutrigenomics? Nutrigenomics studies the interaction between: nutrients, genes, and biological systems. Unlike traditional nutrition science, nutrigenomics asks deeper questions such as: How do nutrients influence gene expression? Can diet activate or suppress cancer-related pathways? Why do people respond differently to the same foods? How do gen...

Cancer treatment is increasingly moving beyond the idea that tumors are driven only by genetic mutations. A growing body of research now suggests that metabolism — including glucose levels, insulin signaling, mitochondrial function, fatty liver disease, and ketone metabolism — may strongly influence how cancers grow, spread, and respond to treatment. One of the clearest examples of this connection is now emerging in liver cancer , where metabolic disease has become one of the fastest-growing causes worldwide. Researchers are beginning to explore whether improving metabolic health could potentially influence: cancer risk, tumor progression, inflammation, and even responses to immunotherapy. The Global Rise of Metabolic Disease Modern metabolic disease includes: obesity insulin resistance type 2 diabetes metabolic syndrome fatty liver disease These conditions are now increasingly linked to cancer development. Particularly: liver cancer colorectal cancer pancreatic cancer breast cancer en...

In modern oncology, treatment has traditionally centered on surgery, chemotherapy, radiation, and immunotherapy. However, a growing body of discussion in clinical and research circles is exploring a complementary question: Can diet and metabolism influence cancer progression and treatment response? This perspective views cancer not only as a genetic disease but also as a metabolic disorder shaped by the body’s internal environment . While not a replacement for standard treatment, nutritional and metabolic strategies are increasingly being examined as potential supportive approaches. Cancer as a Metabolic Disease: The Emerging Perspective One of the most discussed concepts in cancer biology is metabolic reprogramming—how cancer cells alter their energy usage to support rapid growth. A commonly referenced phenomenon is the tendency of cancer cells to rely heavily on glucose for energy, even in oxygen-rich conditions. This has led researchers to explore whether: Glucose availability influ...

Cancer treatment has entered the era of precision oncology, where biomarkers can help predict which patients are most likely to benefit from specific therapies. One of the most discussed biomarkers in immunotherapy today is Tumor Mutation Burden (TMB) . But what exactly is TMB? Why does it matter? And does a “high TMB” always mean better responses to immunotherapy? Here’s what patients, caregivers, and healthcare professionals should know in 2026. What Is Tumor Mutation Burden (TMB)? Tumor Mutation Burden refers to the total number of genetic mutations found inside a tumor’s DNA. In simple terms: Some cancers carry only a few mutations. Others accumulate thousands of mutations over time. TMB is usually measured as: mutations per megabase (mut/Mb) A tumor with: 2 mut/Mb = low TMB 10+ mut/Mb = often considered high TMB 20–50+ mut/Mb = very high TMB The idea behind TMB is straightforward: The more mutations a tumor has, the more “abnormal” proteins (neoantigens) it may produce — making it...